NKGen Biotech, Inc. (NKGN)

OTCMKTS · Delayed Price · Currency is USD

0.2997

+0.0297 (11.00%)

May 13, 2025, 3:52 PM EDT

NKGen Biotech Employees

NKGen Biotech had 63 employees as of December 31, 2023.

Employees

63

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$769,492

Market Cap

15.63M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
Endo Inc.	3,116
Tian'an Technology Group	8
CytoDyn	9
Glass House Brands	374
Elite Pharmaceuticals	64
Northwest Biotherapeutics	25
American Oncology Network	1,914
Silence Therapeutics	116

Employee Rankings

NKGen Biotech News

6 days ago - NKGen Biotech Chairman & CEO Paul Y. Song, M.D. - GlobeNewsWire
4 weeks ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - Benzinga
4 weeks ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - GlobeNewsWire
5 weeks ago - NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
7 weeks ago - NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
2 months ago - NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - GlobeNewsWire
2 months ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
2 months ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire